SERA vs. FLGT, SBC, TALK, DCGO, INNV, CELC, EHAB, PSNL, VMD, and AIRS
Should you be buying Sera Prognostics stock or one of its competitors? The main competitors of Sera Prognostics include Fulgent Genetics (FLGT), SBC Medical Group (SBC), Talkspace (TALK), DocGo (DCGO), InnovAge (INNV), Celcuity (CELC), Enhabit (EHAB), Personalis (PSNL), Viemed Healthcare (VMD), and AirSculpt Technologies (AIRS). These companies are all part of the "healthcare" industry.
Sera Prognostics vs.
Sera Prognostics (NASDAQ:SERA) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, community ranking, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
Sera Prognostics has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500.
In the previous week, Fulgent Genetics had 13 more articles in the media than Sera Prognostics. MarketBeat recorded 16 mentions for Fulgent Genetics and 3 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.85 beat Fulgent Genetics' score of 0.50 indicating that Sera Prognostics is being referred to more favorably in the media.
Sera Prognostics has higher earnings, but lower revenue than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.
Fulgent Genetics has a consensus target price of $22.00, indicating a potential upside of 43.98%. Given Fulgent Genetics' higher possible upside, analysts clearly believe Fulgent Genetics is more favorable than Sera Prognostics.
Sera Prognostics has a net margin of 0.00% compared to Fulgent Genetics' net margin of -59.39%. Fulgent Genetics' return on equity of -1.81% beat Sera Prognostics' return on equity.
Fulgent Genetics received 234 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 60.10% of users gave Fulgent Genetics an outperform vote while only 38.46% of users gave Sera Prognostics an outperform vote.
54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 15.8% of Sera Prognostics shares are owned by company insiders. Comparatively, 31.8% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Fulgent Genetics beats Sera Prognostics on 10 of the 18 factors compared between the two stocks.
Get Sera Prognostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SERA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sera Prognostics Competitors List
Related Companies and Tools
This page (NASDAQ:SERA) was last updated on 3/4/2025 by MarketBeat.com Staff
